aibio
Company Updates ·
Bionano reports second quarter 2026 revenue of $8.2 million
Consumables revenue rose 31%, and the company completed the retirement of its senior secured convertible debentures.
BNGO Bionano Genomics, Inc.
Bionano Genomics (BNGO) news BNGO convertible notes news
Latest Bionano Genomics news
- Company Updates
Bionano reports first quarter 2026 revenue of $6.7 million
Consumables revenue grew 20%, and the company guided to full-year 2026 revenue of $30 to $33 million.
Bionano Genomics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $11.4 million | $24.8 million |
| Net income (loss) | -$26.4 million | -$112.0 million |
| Cash from operations | -$16.3 million | -$68.9 million |
| Cash and equivalents | $3.0 million | $9.2 million |
| Short-term investments | $16.3 million | $302,000 |
Questions about Bionano Genomics
Has Bionano Genomics sold convertible notes?
Our latest story on this, dated Aug 10, 2026: "Bionano reports second quarter 2026 revenue of $8.2 million". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Bionano Genomics?
Bionano Genomics, Inc. trades under the ticker BNGO on NASDAQ.
Where is Bionano Genomics listed?
Bionano Genomics, Inc. is listed on NASDAQ.
Which country or territory is Bionano Genomics listed under?
Our directory records Bionano Genomics, Inc. under United States.
Does aibio.space cover Bionano Genomics?
aibio.space lists Bionano Genomics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Is Bionano Genomics profitable?
Bionano Genomics, Inc. reported a net loss of $26.4 million for the fiscal year ended Dec 31, 2025, and used $16.3 million of cash in operations, per its annual report to the SEC.
How much does Bionano Genomics spend on research and development?
$11.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Bionano Genomics have?
$9.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Bionano Genomics (BNGO) stock news?
Our latest story on Bionano Genomics, dated Aug 10, 2026: "Bionano reports second quarter 2026 revenue of $8.2 million". Consumables revenue rose 31%, and the company completed the retirement of its senior secured convertible debentures. Source.
How can I follow Bionano Genomics (BNGO) news?
Press Follow on this page to add Bionano Genomics to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming Bionano Genomics so far, in Company Updates.
Investor discussion: Bionano Genomics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Stock chart
Listing details
- Company
- Bionano Genomics, Inc.
- Ticker
- BNGO
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction